Influenza

Global Influenza Diagnostics Market by Test Type, End User and Region - Forecast to 2026

Retrieved on: 
Wednesday, August 26, 2020
Influenza, RTT, Specificity

DUBLIN, Aug. 26, 2020 /PRNewswire/ -- The "Influenza Diagnostics Market by Test Type, by End-user, Geography - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 26, 2020 /PRNewswire/ -- The "Influenza Diagnostics Market by Test Type, by End-user, Geography - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The Global Influenza Diagnostics Market is predicted to grow at a CAGR of 6.3% during the forecast period, expecting to grow from $4 billion in 2020 to a value of $5.8 billion in 2026.
  • Although some aspects, such as increasing hospital expenses, the discrepancy in the test sensitivity & test specificity, and restricted regulations are hampering the influenza diagnostics market growth.
  • This report gives an in-depth analysis of the drivers, challenges, and opportunities of the influenza diagnostics market.

COVID-19 Pandemic Impact on Global Upper Respiratory Tract Infection Treatment Market 2020-2024 | Technavio

Retrieved on: 
Wednesday, August 26, 2020
Health, Infectious diseases, Medical specialties, Health, Medicine, Infectious diseases, Respiratory tract infection, Coronavirus disease, Respiratory tract, Infection, Upper respiratory tract infection, Influenza, Chest infection

With the surging growth of COVID-19 pandemic, the Health Care market is anticipated to have a Direct impact during the forecast period.

Key Points: 
  • With the surging growth of COVID-19 pandemic, the Health Care market is anticipated to have a Direct impact during the forecast period.
  • View market snapshot before purchasing
    Rising incidence and prevalence of upper respiratory tract infections has been an instrumental factor in influencing the growth of upper respiratory tract infection treatment market.
  • Technavio offers custom research analysis on the crucial pointers to highlight the impact of COVID-19 on the market across the supply chain.
  • Key Considerations for Market Forecast:
    Get more insights about the global trends impacting the future of upper respiratory tract infection treatment market, Request Free Sample @ https://www.technavio.com/talk-to-us?report=IRTNTR43396
    Upper Respiratory Tract Infection Treatment Market 2020-2024: Vendor Analysis
    The market is concentrated, and the degree of concentration will accelerate during the forecast period.

Global Influenza Diagnostics Market Outlook 2020-2026 - Influenza Testing Volumes Burgeoning due to the Outbreak of COVID-19 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 25, 2020
Medical devices, Health, Influenza, RTT, Specificity, Health, Medicine

The "Influenza Diagnostics Market by Test Type, by End-user, Geography - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Influenza Diagnostics Market by Test Type, by End-user, Geography - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
  • Although some aspects, such as increasing hospital expenses, the discrepancy in the test sensitivity & test specificity, and restricted regulations are hampering the influenza diagnostics market growth.
  • Somehow, the rising cost of kits and reagents in the influenza diagnostics is the major aspect hindering the market growth.
  • This report gives an in-depth analysis of the drivers, challenges, and opportunities of the influenza diagnostics market.

New Mucinex® GeoVitalPredictor (GVP) Puts Americans One Step Ahead of Cold and Flu Outbreaks

Retrieved on: 
Friday, August 21, 2020
Articles, Health, Infectious diseases, RTT, Public Health Emergency of International Concern, Expectorants, Glycerols, Guaifenesin, Uric acid, COVID-19 pandemic, Influenza, Pandemic

During the early stages of the COVID-19 pandemic, consumers across the country were inundated with conflicting healthcare messages and also experienced empty store shelves.

Key Points: 
  • During the early stages of the COVID-19 pandemic, consumers across the country were inundated with conflicting healthcare messages and also experienced empty store shelves.
  • As a result, worries grew from conflicting healthcare messages and having access to basic supplies, including go-to over-the-counter remedies.
  • Equipped with this information, Mucinex will be able to see where cold and flu relief is needed most and nimbly direct the supply of its cold and flu remedy to retail locations in counties where outbreaks are happening, and consumer need and demand are high.
  • For more information on this partnership and to learn where you can find Mucinex products, visit Mucinex.com.

BiondVax Announces Second Quarter 2020 Financial Results

Retrieved on: 
Thursday, August 20, 2020
RTT, Health care, Health, Medical specialties, BiondVax, Influenza vaccine, Influenza

JERUSALEM, Aug. 20, 2020 /PRNewswire/ --BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal influenza vaccine candidate, today announced its second quarter financial results for the quarter ended June 30, 2020.

Key Points: 
  • JERUSALEM, Aug. 20, 2020 /PRNewswire/ --BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal influenza vaccine candidate, today announced its second quarter financial results for the quarter ended June 30, 2020.
  • Total operating expenses for the second quarter were NIS 16.0 million (approximately $4.61million) compared with NIS 19.7million for the second quarter of 2019.
  • R&D expenses for the second quarter amounted to NIS 11.9 million (approximately $3.4 million) compared with NIS 15.2 million for the second quarter of 2019.
  • Net loss for the second quarter was NIS 42 million (approximately $12.1million) compared to net loss of NIS 47.4 million for the second quarter of 2019.

Flu Shots Now Available at Stop & Shop Pharmacies

Retrieved on: 
Thursday, August 20, 2020
Health, Articles, Vaccines, Influenza, Vaccine, Virology, Influenza vaccine, Pharmacy, Flu season, Vaccination, Pharmacist, Independent pharmacy

Stop & Shop is taking extensive health and safety precautions at its pharmacies and has secured additional stock of the flu vaccine, anticipating higher demand as a result of the COVID-19 pandemic.

Key Points: 
  • Stop & Shop is taking extensive health and safety precautions at its pharmacies and has secured additional stock of the flu vaccine, anticipating higher demand as a result of the COVID-19 pandemic.
  • Stop & Shop has enhanced its health and safety protocols for vaccinations at all of its pharmacies.
  • Stop & Shop is ready to take care of its communities this flu season, shares Katie Thornell, Director of Pharmacy at Stop & Shop.
  • Stop & Shop pharmacies also have an ample supply of shingles and pneumonia vaccines available, and customers should consult their local Stop & Shop pharmacist on all other immunizations that may be available and valuable to them and their families.

Rite Aid Prepares for Flu Season: Flu Shots Now Available at All Rite Aid Locations

Retrieved on: 
Tuesday, August 18, 2020
Discount, Variety, Infectious diseases, Specialty, Convenience store, Other Health, Health, Pharmaceutical, General Health, Retail, Health, Influenza, Rite Aid, Flu season, Influenza vaccine, Influenza A virus subtype H1N1, Pharmacy, Medicare, Articles

Rite Aid (NYSE: RAD) announced today that seasonal flu shots are now available at all Rite Aid locations.

Key Points: 
  • Rite Aid (NYSE: RAD) announced today that seasonal flu shots are now available at all Rite Aid locations.
  • We are prepared to immunize more individuals and families during the upcoming flu season than in any previous year.
  • Flu shots are covered by most insurance plans, including Medicare Part B, and are available during pharmacy hours; no appointment is necessary.
  • Rite Aid Corporation is on the front lines of delivering healthcare services and retail products to more than 1.6 million Americans daily.

Avoiding COVID and Flu: Welltok Uses Data to Predict Risk and Drive Flu Shots

Retrieved on: 
Tuesday, August 11, 2020
RTT, Medical specialties, Health, Infectious diseases, Influenza, Influenza vaccine, Vaccines, Flu season, Coronavirus disease, Swine flu pandemic

Welltok , a consumer activation solutions company, has a long track record of identifying people more susceptible to contracting the flu virus and activating them to get a flu shot.

Key Points: 
  • Welltok , a consumer activation solutions company, has a long track record of identifying people more susceptible to contracting the flu virus and activating them to get a flu shot.
  • With symptoms similar to COVID, minimizing the infection and spread of the flu is critical to avoid further strain to our health system.
  • Vaccination is particularly important during the 2020-2021 flu season for groups who are at higher risk for complications from flu as they are often at higher risk for COVID-19 too.
  • Only Welltok uses a smart mix of proprietary data and machine learning to engage consumers in personalized and rewarding ways to drive action.

Kanazawa University research: Real-time observation of structural dynamic of influenza A hemagglutinin during viral entry

Retrieved on: 
Friday, August 7, 2020
Proteins, Medical specialties, Branches of biology, Influenza A virus, Viral structural proteins, Hemagglutinin, Protein families, Orthomyxoviridae, Influenza, Viral neuraminidase, Influenza C virus

The devastating respiratory virus, influenza A virus, utilize its hemagglutinin (HA) proteins to search for suitable host cells.

Key Points: 
  • The devastating respiratory virus, influenza A virus, utilize its hemagglutinin (HA) proteins to search for suitable host cells.
  • More strikingly, HA undergoes structural change to mediate viral membrane to fuse with host endosomal membrane to form a hole in order to release viral components.
  • Influenza A hemagglutinin (HA) is a protein residing on the surface of influenza A virus (the culprit that causes 'the flu' or influenza), playing a key role in viral infectivity.
  • High-speed AFM reveals molecular dynamic of human influenza A hemagglutinin and its interaction with exosomes, Nano Letters Published online on July 27, 2020.

Kanazawa University research: Real-time observation of structural dynamic of influenza A hemagglutinin during viral entry

Retrieved on: 
Friday, August 7, 2020
Proteins, Medical specialties, Branches of biology, Influenza A virus, Viral structural proteins, Hemagglutinin, Protein families, Orthomyxoviridae, Influenza, Viral neuraminidase, Influenza C virus

The devastating respiratory virus, influenza A virus, utilize its hemagglutinin (HA) proteins to search for suitable host cells.

Key Points: 
  • The devastating respiratory virus, influenza A virus, utilize its hemagglutinin (HA) proteins to search for suitable host cells.
  • More strikingly, HA undergoes structural change to mediate viral membrane to fuse with host endosomal membrane to form a hole in order to release viral components.
  • Influenza A hemagglutinin (HA) is a protein residing on the surface of influenza A virus (the culprit that causes 'the flu' or influenza), playing a key role in viral infectivity.
  • High-speed AFM reveals molecular dynamic of human influenza A hemagglutinin and its interaction with exosomes, Nano Letters Published online on July 27, 2020.